Morgan Stanley Maintains Overweight on Generate Biomedicines, Lowers Price Target to $21
Benzinga Newsdesk 12 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and lowers the price target from $22 to $21.
Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and lowers the price target from $22 to $21.
